Compare OIS & PRME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | OIS | PRME |
|---|---|---|
| Founded | 1995 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Medicinal Chemicals and Botanical Products |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 552.6M | 553.2M |
| IPO Year | 2000 | 2022 |
| Metric | OIS | PRME |
|---|---|---|
| Price | $8.67 | $3.64 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 2 | 6 |
| Target Price | ★ $14.00 | $7.56 |
| AVG Volume (30 Days) | 611.2K | ★ 2.6M |
| Earning Date | 05-05-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 18.18 |
| EPS | ★ 0.12 | N/A |
| Revenue | ★ $1,088,133,000.00 | $4,632,000.00 |
| Revenue This Year | $3.12 | $7.06 |
| Revenue Next Year | $5.89 | $47.01 |
| P/E Ratio | $69.08 | ★ N/A |
| Revenue Growth | ★ 62.26 | 55.28 |
| 52 Week Low | $5.40 | $2.67 |
| 52 Week High | $14.50 | $6.94 |
| Indicator | OIS | PRME |
|---|---|---|
| Relative Strength Index (RSI) | 52.55 | 57.95 |
| Support Level | $8.60 | $3.16 |
| Resistance Level | $8.86 | $3.68 |
| Average True Range (ATR) | 0.36 | 0.23 |
| MACD | -0.04 | 0.06 |
| Stochastic Oscillator | 50.43 | 86.11 |
Oil States International Inc is a provider of manufactured products and services to customers in the energy, military and industrial sectors. The company operates through three business segments - Offshore Manufactured Products, Completion and Production Services and Downhole Technologies. Its customers include many national oil and natural gas companies, and independent oil and natural gas companies, offshore drilling companies and other oilfield service, defense and industrial companies.
Prime Medicine Inc is a biotechnology company focused on developing a new class of genetic medicines designed to provide durable, and potentially curative, treatment options for patients with diseases driven by defined genetic alterations, acquired cellular dysfunction, or dysregulated gene expression. Its program, PM577 for Wilson Disease, is designed to initially correct the H1069Q mutation in the ATP7B gene and is supported by preclinical data showing targeted correction and restoration of copper homeostasis in animal models. In addition, PM647 is being developed for alpha-1 antitrypsin deficiency, or AATD, another liver targeted disease with substantial unmet need.